More on BBIO

- Summary
- Chart
- Profile
- Historical

Data

- Earnings (+37.9% Growth)
- Ratings (8.9 Score)
- Holders

Upcoming Events

- Earnings (7/30/26)

News

- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks
More...

BridgeBio Pharma (NQ:BBIO)
Delayed: 67.41 -0.27 (0.4%)
Prev. Close $67.68  
Open$67.10 
52 Wk High$ 
52 Wk Low$ 
Day High$69.42 
Day Low$67.02 
P/E N/A  
EPS$ 
Volume2,128,416 

Friends, Peers and Foes (?): PFE, HLXB, ARGX, CNTA, OWL (more...)

Jun 8, 2026 06:01 PM Form 4 BridgeBio Pharma, Inc. For: Jun 04 Filed by: Kumar Neil
Jun 8, 2026 10:05 AM Mizuho on BridgeBio Pharma (BBIO): 'We believe that any such potential transient weakness could represent a potential entry point opportunity'
Jun 3, 2026 05:59 AM Canaccord Starts BridgeBio Pharma (BBIO) at Buy
May 29, 2026 04:49 PM Form SCHEDULE 13G BridgeBio Pharma, Inc. Filed by: Farallon Capital Partners, L.P.
May 27, 2026 04:02 PM Form 8-K BridgeBio Pharma, Inc. For: May 27
May 27, 2026 07:30 AM BridgeBio receives FDA priority review for muscular dystrophy drug
May 27, 2026 07:30 AM BridgeBio Announces FDA Acceptance and Priority Review of NDA for BBP-418 for LGMD2I/R9
May 26, 2026 04:54 PM Form 4 BridgeBio Pharma, Inc. For: May 21 Filed by: Kumar Neil
May 26, 2026 03:49 AM Raymond James Downgrades BridgeBio Pharma (BBIO) to Market Perform
May 21, 2026 04:32 PM Form 144 BridgeBio Pharma, Inc. Filed by: Kumar Neil
View All Articles

Entities mentioned with BBIO

View All Entities